MA29907B1 - Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l'eugenol, le thymol, le borneol, le carvacrol et les ionones alpha - et beta- - Google Patents

Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l'eugenol, le thymol, le borneol, le carvacrol et les ionones alpha - et beta-

Info

Publication number
MA29907B1
MA29907B1 MA30529A MA30529A MA29907B1 MA 29907 B1 MA29907 B1 MA 29907B1 MA 30529 A MA30529 A MA 30529A MA 30529 A MA30529 A MA 30529A MA 29907 B1 MA29907 B1 MA 29907B1
Authority
MA
Morocco
Prior art keywords
carveol
carvacrol
borneol
thymol
eugenol
Prior art date
Application number
MA30529A
Other languages
English (en)
French (fr)
Inventor
Adnane Remmal
Original Assignee
Advanced Scient Developments
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Scient Developments filed Critical Advanced Scient Developments
Publication of MA29907B1 publication Critical patent/MA29907B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA30529A 2005-05-13 2007-12-28 Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l'eugenol, le thymol, le borneol, le carvacrol et les ionones alpha - et beta- MA29907B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2005/001317 WO2006120496A1 (fr) 2005-05-13 2005-05-13 Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l’ eugenol, le thymol, le borneol, et le carvacrol

Publications (1)

Publication Number Publication Date
MA29907B1 true MA29907B1 (fr) 2008-11-03

Family

ID=35427301

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30529A MA29907B1 (fr) 2005-05-13 2007-12-28 Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l'eugenol, le thymol, le borneol, le carvacrol et les ionones alpha - et beta-

Country Status (13)

Country Link
US (1) US20080214568A1 (https=)
EP (1) EP1879654B1 (https=)
JP (1) JP5410747B2 (https=)
CN (1) CN101189044B (https=)
BR (1) BRPI0610132B8 (https=)
CA (1) CA2607561C (https=)
DK (1) DK1879654T3 (https=)
EA (1) EA014068B1 (https=)
ES (1) ES2390472T3 (https=)
MA (1) MA29907B1 (https=)
PT (1) PT1879654E (https=)
TN (1) TNSN07425A1 (https=)
WO (2) WO2006120496A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034570A1 (en) 2004-09-28 2006-04-06 Chemaphor Inc. Compositions and methods for promoting weight gain and feed conversion
EP2214656B1 (en) * 2007-10-26 2018-12-05 Avivagen Inc. Compositions and methods for enhancing immune response
AU2010242502B2 (en) 2009-04-30 2016-11-10 Avivagen Inc. Methods and compositions for improving the health of animals
AU2010297406B2 (en) 2009-09-24 2013-10-17 Unilever Plc Disinfecting agent comprising eugenol, terpineol and thymol
WO2012076310A1 (en) 2010-12-07 2012-06-14 Unilever Nv An oral care composition
CN102550610B (zh) * 2010-12-07 2014-12-10 菲勒斯株式会社 含有从红松球果中提取的植物杀菌素的天然抗菌剂及包含它的水果病害防除原料
EP2672845A2 (en) * 2011-02-07 2013-12-18 Firmenich SA Antifungal flavouring ingredients and compositions
MX2014005405A (es) 2011-11-03 2014-06-23 Unilever Nv Una composicion de limpieza personal.
JP5925605B2 (ja) * 2012-06-04 2016-05-25 花王株式会社 リパーゼ活性阻害剤、抗真菌剤、及びフケ抑制剤
IL312208A (en) 2014-10-08 2024-06-01 Pacific Northwest Res Institute Methods and preparations for increasing the potency of antifungal agents
CN104642326B (zh) * 2015-02-16 2016-02-10 河南科技学院 一种含戊苯吡菌胺和香芹酚的杀菌组合物及其用途
WO2017209588A2 (fr) 2016-06-02 2017-12-07 Advanced Scientific Developements Formulation pharmaceutique de cinéol et d'amoxicilline
US10918647B2 (en) 2016-07-26 2021-02-16 University Of Southern California Selective bromodomain inhibition of fungal Bdf1
CN113116916B (zh) * 2021-05-25 2023-07-04 河北医科大学第二医院 一种治疗妇科疾病的药物组合物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294645A (en) * 1993-06-14 1994-03-15 Doyle E. Chastain Using menth-1-en-9-ol to kill bacteria, yeast, and fungi
CA2106032C (en) * 1993-09-13 1995-11-07 Gamini Weeratunga Methods for the manufacture of fluconazole and forms thereof, intermediates useful in the manufacture thereof, and combinations comprising fluconazole
MX9602570A (es) * 1994-01-14 1997-04-30 Xoma Corp Metodos y materiales anti-fungosos.
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6319507B1 (en) * 1997-05-02 2001-11-20 Kobo Products, Inc. Agar gel bead composition and method
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
AU2002217316A1 (en) * 2001-01-03 2002-07-30 Medpharma Plc Use of terpenes for the treatment of digestive tract infections
JP2002284702A (ja) * 2001-01-19 2002-10-03 Teika Seiyaku Kk 外用抗真菌製剤
US20030064948A1 (en) * 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
JP2002363070A (ja) * 2001-06-06 2002-12-18 Yuutoku Yakuhin Kogyo Kk 経皮吸収貼付剤
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
US20030180349A1 (en) * 2001-12-07 2003-09-25 Franklin Lanny U. Respiratory infection prevention and treatment with terpene-containing compositions
US20030225003A1 (en) * 2002-04-18 2003-12-04 Dusan Ninkov Antimicrobial therapeutic compositions for oral and topical use
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
WO2004089357A2 (en) * 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil

Also Published As

Publication number Publication date
EP1879654B1 (fr) 2012-07-04
EA200702482A1 (ru) 2008-04-28
CA2607561A1 (fr) 2006-11-16
CA2607561C (fr) 2014-02-04
TNSN07425A1 (fr) 2009-03-17
BRPI0610132A2 (pt) 2012-09-25
EA014068B1 (ru) 2010-08-30
DK1879654T3 (da) 2012-08-20
ES2390472T3 (es) 2012-11-13
BRPI0610132B8 (pt) 2021-05-25
EP1879654A2 (fr) 2008-01-23
JP5410747B2 (ja) 2014-02-05
WO2006120565A2 (fr) 2006-11-16
CN101189044B (zh) 2011-12-07
US20080214568A1 (en) 2008-09-04
BRPI0610132B1 (pt) 2020-08-11
WO2006120496A1 (fr) 2006-11-16
WO2006120565A3 (fr) 2007-08-23
JP2008540506A (ja) 2008-11-20
CN101189044A (zh) 2008-05-28
PT1879654E (pt) 2012-08-29

Similar Documents

Publication Publication Date Title
MA29907B1 (fr) Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l'eugenol, le thymol, le borneol, le carvacrol et les ionones alpha - et beta-
TNSN07424A1 (fr) Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol
MA29573B1 (fr) Composition pharmaceutique comprenant un antiviral , un antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol , le thymol, l' eugenol, le borneol et le carvacrol
WO2003105800A3 (de) Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen
CA2176840A1 (fr) Association d'un compose a activite anti-microbienne et d'un monoalkylether de glycerol
MA30765B1 (fr) Derives innovants du thiophene
BRPI0409250B8 (pt) Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar
TW200642694A (en) Anti-M-CSF antibody compositions
WO2002022627A3 (en) Ligands for metabotropic glutamate receptors
WO2004047838A3 (de) Pharmazeutische zusammensetzung aus beta-3-adrenozeptor-agonisten und antimuskarinika
ES2184293T3 (es) Composiciones farmaceuticas administrables por via oral que comprenden una benzhidrilpiperazina y una ciclodextrina.
TNSN04241A1 (fr) Composition herbicide
WO2006081363A3 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
MXPA05012278A (es) Composiciones para suministrar peptido yy y combatientes pyy.
CY1108676T1 (el) Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων
WO2006029155A3 (en) Improved ghb compositions
ATE357928T1 (de) Pharmazeutische zusammensetzung für thrombinpeptidderivaten
MA29333B1 (fr) Preparations pharmaceutiques d'aerosol pour aerosols-doseurs pressurises contenant un agent sequestrant
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2003061572A3 (en) Anti-inflammatory formulations
WO2007011958A3 (en) Intraoral dosage forms of glucagon
BRPI0407596A (pt) formulações orais semi-sólidas para liberação imediata compreendendo um agente anticáncer hidrofóbico, um glicerìdio poliglicolisado e veìculo hidrofìlico
FR3119314B1 (fr) Nanocapsule lipidique comprenant au moins un composé aminothiolester ou un de ses dérivés pharmaceutiquement acceptable
TNSN06217A1 (fr) Forme posologique solide
SV2006002054A (es) Formas de dosificacion y composiciones farmaceuticas ref. 305122